127 related articles for article (PubMed ID: 19702629)
1. Risk factors for and clinical characteristics of severe hyperlactataemia in patients receiving antiretroviral therapy: a case-control study.
Osler M; Stead D; Rebe K; Meintjes G; Boulle A
HIV Med; 2010 Feb; 11(2):121-9. PubMed ID: 19702629
[TBL] [Abstract][Full Text] [Related]
2. Severe hyperlactataemia complicating stavudine first-line antiretroviral therapy in South Africa.
Stead D; Osler M; Boulle A; Rebe K; Meintjes G
Antivir Ther; 2008; 13(7):937-43. PubMed ID: 19043928
[TBL] [Abstract][Full Text] [Related]
3. Risk factors for mortality in symptomatic hyperlactatemia among HIV-infected patients receiving antiretroviral therapy in a resource-limited setting.
Manosuthi W; Prasithsirikul W; Chumpathat N; Suntisuklappon B; Athichathanabadi C; Chimsuntorn S; Sungkanuparph S
Int J Infect Dis; 2008 Nov; 12(6):582-6. PubMed ID: 18337140
[TBL] [Abstract][Full Text] [Related]
4. Hyperlactataemia and lactic acidosis in HIV-infected patients receiving antiretroviral therapy.
Calza L; Manfredi R; Chiodo F
Clin Nutr; 2005 Feb; 24(1):5-15. PubMed ID: 15681097
[TBL] [Abstract][Full Text] [Related]
5. A high incidence of lactic acidosis and symptomatic hyperlactatemia in women receiving highly active antiretroviral therapy in Soweto, South Africa.
Bolhaar MG; Karstaedt AS
Clin Infect Dis; 2007 Jul; 45(2):254-60. PubMed ID: 17578788
[TBL] [Abstract][Full Text] [Related]
6. Stavudine- and nevirapine-related drug toxicity while on generic fixed-dose antiretroviral treatment: incidence, timing and risk factors in a three-year cohort in Kigali, Rwanda.
van Griensven J; Zachariah R; Rasschaert F; Mugabo J; Atté EF; Reid T
Trans R Soc Trop Med Hyg; 2010 Feb; 104(2):148-53. PubMed ID: 19732926
[TBL] [Abstract][Full Text] [Related]
7. Lactic acidosis and symptomatic hyperlactataemia in a randomized trial of first-line therapy in HIV-infected adults in South Africa.
Dlamini J; Ledwaba L; Mokwena N; Mokhathi T; Orsega S; Tsoku M; Kowo H; Proschan M; Khabo P; Maja P; Hadigan C
Antivir Ther; 2011; 16(4):605-9. PubMed ID: 21685549
[TBL] [Abstract][Full Text] [Related]
8. Lactic acidosis associated with stavudine administration: a report of five cases.
Mokrzycki MH; Harris C; May H; Laut J; Palmisano J
Clin Infect Dis; 2000 Jan; 30(1):198-200. PubMed ID: 10619755
[TBL] [Abstract][Full Text] [Related]
9. Stavudine-induced hyperlactatemia/lactic acidosis at a tertiary communicable diseases clinic in South Africa.
Hernández Pérez E; Dawood H
J Int Assoc Physicians AIDS Care (Chic); 2010; 9(2):109-12. PubMed ID: 20484736
[TBL] [Abstract][Full Text] [Related]
10. Lactic acidosis and antiretroviral therapy: a case report and literature review.
Marra A; Lewi D; Lanzoni V; Wey SB; Odashiro LN; Gomes PS; Silva E
Braz J Infect Dis; 2000 Jun; 4(3):151-5. PubMed ID: 10934499
[TBL] [Abstract][Full Text] [Related]
11. Hyperlactataemia in HIV-infected patients: the role of NRTI-treatment.
Vrouenraets SM; Treskes M; Regez RM; Troost N; Smulders YM; Weigel HM; Frissen PH; Brinkman K
Antivir Ther; 2002 Dec; 7(4):239-44. PubMed ID: 12553477
[TBL] [Abstract][Full Text] [Related]
12. Fatal lactic acidosis associated with highly active antiretroviral therapy in patients with advanced human immunodeficiency virus infection in Taiwan.
Sheng WH; Hsieh SM; Lee SC; Chen MY; Wang JT; Hung CC; Chang SC
Int J STD AIDS; 2004 Apr; 15(4):249-53. PubMed ID: 15075019
[TBL] [Abstract][Full Text] [Related]
13. Impact of antiretroviral choice on hypercholesterolaemia events: the role of the nucleoside reverse transcriptase inhibitor backbone.
Jones R; Sawleshwarkar S; Michailidis C; Jackson A; Mandalia S; Stebbing J; Bower M; Nelson M; Gazzard BG; Moyle GJ
HIV Med; 2005 Nov; 6(6):396-402. PubMed ID: 16268821
[TBL] [Abstract][Full Text] [Related]
14. Risk factors for and outcome of hyperlactatemia in HIV-infected persons: is there a need for routine lactate monitoring?
Imhof A; Ledergerber B; Günthard HF; Haupts S; Weber R;
Clin Infect Dis; 2005 Sep; 41(5):721-8. PubMed ID: 16080096
[TBL] [Abstract][Full Text] [Related]
15. Asymptomatic hyperlactataemia: predictive value, natural history and correlates.
McComsey GA; Yau L
Antivir Ther; 2004 Apr; 9(2):205-12. PubMed ID: 15134182
[TBL] [Abstract][Full Text] [Related]
16. Generic fixed-dose combination antiretroviral treatment in resource-poor settings: multicentric observational cohort.
Calmy A; Pinoges L; Szumilin E; Zachariah R; Ford N; Ferradini L;
AIDS; 2006 May; 20(8):1163-9. PubMed ID: 16691068
[TBL] [Abstract][Full Text] [Related]
17. Risk factors for lactic acidosis and severe hyperlactataemia in HIV-1-infected adults exposed to antiretroviral therapy.
Lactic Acidosis International Study Group
AIDS; 2007 Nov; 21(18):2455-64. PubMed ID: 18025882
[TBL] [Abstract][Full Text] [Related]
18. Symptomatic hyperlactatemia associated with nucleoside analogue reverse-transcriptase inhibitor use in HIV-infected patients: a report of 24 cases in a resource-limited setting (Uganda).
Songa PM; Castelnuovo B; Mugasha EB; Ocama P; Kambugu A
Clin Infect Dis; 2007 Aug; 45(4):514-7. PubMed ID: 17638205
[TBL] [Abstract][Full Text] [Related]
19. Resistance profiles after different periods of exposure to a first-line antiretroviral regimen in a Cameroonian cohort of HIV type-1-infected patients.
Soria A; Porten K; Fampou-Toundji JC; Galli L; Mougnutou R; Buard V; Kfutwah A; Vessière A; Rousset D; Teck R; Calmy A; Ciaffi L; Lazzarin A; Gianotti N
Antivir Ther; 2009; 14(3):339-47. PubMed ID: 19474468
[TBL] [Abstract][Full Text] [Related]
20. Hyperlactatemia and antiretroviral therapy: the Swiss HIV Cohort Study.
Boubaker K; Flepp M; Sudre P; Furrer H; Haensel A; Hirschel B; Boggian K; Chave JP; Bernasconi E; Egger M; Opravil M; Rickenbach M; Francioli P; Telenti A
Clin Infect Dis; 2001 Dec; 33(11):1931-7. PubMed ID: 11692306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
